Sanofi to present first Phase II data for SAR302503 for myelofibrosis

Sanofi (Euronext:SAN; NYSE:SNY) will present on Sunday the first Phase II data for myelofibrosis (MF) compound SAR302503 (formerly TG101348), which the pharma gained through its 2010 acquisition of TargeGen Inc. In an abstract released ahead of the American Society of Hematology meeting in Atlanta, Sanofi reported that in a Phase II trial to treat primary MF, post-polycythemia vera MF (PPV-MF) and post-essential thrombocythemia MF (PET-MF), once-daily oral SAR302503 produced mean percent reductions on the primary endpoint of spleen volume as assessed by MRI from baseline to the end of the third 28-day treatment cycle of 30% in the 300 mg arm, 33% in the 400 mg arm and 42% in the 500 mg arm. Median percent reductions on the endpoint were 26% in the 300 mg arm, 31% in the 400 mg arm and 38% in the 500 mg arm. Sanofi said the primary endpoint did not have a pre-specified threshold for comparison of the spleen response against baseline. ...